Rare Disease Focus Novartis Gene Therapies specializes in rare genetic diseases and is advancing gene therapies, presenting an opportunity to position high-value, disease-modifying solutions to specialty clinics, hospitals, and patient advocacy groups focused on SMA and other genetic conditions.

Strategic Partnerships Leverage potential collaboration with large pharma ecosystems and contract research or manufacturing organizations to expand access, leverage distribution channels, and co-develop companion diagnostics or supportive care programs that complement their gene therapy offerings.

Clinical Evidence Push With recent clinical trial setbacks in the broader Novartis portfolio, emphasize monitoring robust real-world data, post-marketing surveillance, and payer-oriented value dossiers to reassure stakeholders and accelerate adoption of their SMA therapy and any pipeline assets.

Regional Expansion Noting recent asset acquisitions and geographical footprint in Asia and India, target regional biopharma distributors, health systems, and research institutions to scale access, local manufacturing partnerships, and training programs for gene therapies.

Digital Engagement The tech stack shows active use of analytics and surveys; propose data-driven outreach, digital trial recruitment support, and customer success analytics to optimize stakeholder engagement, site onboarding, and ongoing support for clinicians and patients.